It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chronic hepatitis B virus (HBV) infection is a major cause of liver disease and cancer worldwide for which there are no curative therapies. The major challenge in curing infection is eradicating or silencing the covalent closed circular DNA (cccDNA) form of the viral genome. The circadian factors BMAL1/CLOCK and REV-ERB are master regulators of the liver transcriptome and yet their role in HBV replication is unknown. We establish a circadian cycling liver cell-model and demonstrate that REV-ERB directly regulates NTCP-dependent hepatitis B and delta virus particle entry. Importantly, we show that pharmacological activation of REV-ERB inhibits HBV infection in vitro and in human liver chimeric mice. We uncover a role for BMAL1 to bind HBV genomes and increase viral promoter activity. Pharmacological inhibition of BMAL1 through REV-ERB ligands reduces pre-genomic RNA and de novo particle secretion. The presence of conserved E-box motifs among members of the Hepadnaviridae family highlight an evolutionarily conserved role for BMAL1 in regulating this family of small DNA viruses.
The circadian factors BMAL1/CLOCK and REV-ERB are master regulators of the human liver transcriptome but their role in hepatitis B virus infection is largely unknown. Here, Zhuang et al. show that REV-ERB regulates hepatitis B virus entry and BMAL1 directly binds HBV DNA and activates viral genome transcription.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 University of Oxford, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
2 University of Oxford, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); National Institute of Infectious Diseases, Department of Virology II, Tokyo, Japan (GRID:grid.410795.e) (ISNI:0000 0001 2220 1880); RIKEN Cluster for Pioneering Research, Wako, Japan (GRID:grid.410795.e)
3 UMR-S1110, Institut de Recherche sur les Maladies Virales et Hépatiques, University of Strasbourg and Inserm, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291)
4 John Radcliffe Hospital, NIHR Oxford Biomedical Research Centre, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492); University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
5 University of Manchester, Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
6 University of Manchester, Division of Pharmacy and Optometry, School of Health Sciences and Manchester Academic Health Sciences Centre, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
7 Università del Piemonte Orientale, Department of Translational Medicine, Novara, Italy (GRID:grid.16563.37) (ISNI:0000000121663741)
8 National Institute of Infectious Diseases, Department of Virology II, Tokyo, Japan (GRID:grid.410795.e) (ISNI:0000 0001 2220 1880); RIKEN Cluster for Pioneering Research, Wako, Japan (GRID:grid.410795.e); Kyoto University, Department of Applied Biological Sciences, Tokyo University of Science Graduate School of Science and Technology, Japan and Institute for Frontier Life and Medical Sciences, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)
9 UMR-S1110, Institut de Recherche sur les Maladies Virales et Hépatiques, University of Strasbourg and Inserm, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291); Hopitaux Universitaire de Strasbourg, Strasbourg and Institut Universitaire de France, Pôle Hépato-Digestif, Institut Hopitalo-Universitaire (IHU), Paris, France (GRID:grid.440891.0) (ISNI:0000 0001 1931 4817)